Accessibility Menu
Ono Pharmaceutical logo

Ono Pharmaceutical(OTC) OPHLY

Market Cap$7.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+31%
5 Year-29%
1 Year+42%
1 Month+5%
$5.30
+2.87%
+0.15Today
Ono Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 5.152026-09-02
Ono Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.17%USD 5.142026-08-26
1 month+4.89%USD 4.912026-08-03
3 month+13.48%USD 4.542026-06-04
Year to date+15.02%USD 4.482025-12-31
1 year+42.1%USD 3.632025-09-02
3 year-7.92%USD 5.602023-09-01
5 year-28.57%USD 7.212021-09-03
Since inception+31.07%USD 3.932012-10-01

Ono Pharmaceutical Financials at a Glance

Market Cap

$7.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥512.91B

Net Income (TTM)

¥77.58B

EPS (TTM)

$0.35

P/E Ratio

14.64

Dividend

$0.17

Beta (Volatility)

0.21 (Low)

Price

$5.30

Volume

24,788

Open

$5.27

Previous Close

$5.30

Daily Range

$5.26 - $5.30

52-Week Range

$3.71 - $5.75

Estimated Earnings Date

Nov 2, 2026

OPHLY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is a global leader in the research, development, and commercialization of pharmaceutical products, particularly in oncology. The company offers a diverse portfolio of established treatments and is committed to advancing medical innovations across various therapeutic areas.

Products and Services
  • Oncology treatments including OPDIVO and KYPROLIS
  • Diabetes and cardiovascular therapies such as GLACTIV and CORALAN
  • Innovative solutions for neurological and inflammatory disorders
Growth Outlook
  • Strong pipeline targeting multiple cancer types and chronic diseases
  • Recent quarterly revenue growth indicates robust market demand
  • Investment in R&D expected to drive future product launches
Financial Highlights
  • Recent quarterly revenue of 117.69 billion JPY, reflecting strong performance
  • TTM net income of 24.47 billion JPY, showcasing profitability
  • Current ratio of 3.28 indicates strong liquidity position
Ono Pharmaceutical Co., Ltd. has established itself as a significant player in the healthcare sector, particularly in oncology. The company's diverse product offerings cater to various medical needs, from cancer treatments to therapies for chronic conditions. The growth outlook remains positive, supported by a strong pipeline and recent revenue trends. Financially, the company demonstrates solid profitability and liquidity, making it an attractive option for potential investors interested in the pharmaceutical industry.
AI Generated • Aug 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4,206

CEO

Gyo Sagara

Website

www.ono-pharma.com

Headquarters

Osaka, OS 541-8564, JP

OPHLY Financials

Key Financial Metrics (TTM)

Gross Margin

73.56%

Operating Margin

22.07%

Net Income Margin

15.13%

Return on Equity

9.08%

Return on Capital

11.23%

Return on Assets

7.04%

Earnings Yield

6.83%

Dividend Yield

3.26%

Payout Ratio

49.26%

Stock Overview

Market Cap

$7.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.41B

Volume

24.79K

Avg. Volume

40.28K

Financials (TTM)

Gross Profit

¥377.27B

Operating Income

¥113.17B

EBITDA

¥151.93B

Operating Cash Flow

¥137.84B

Capital Expenditure

-¥5.76B

Free Cash Flow

¥132.07B

Cash & ST Invst.

¥219.74B

Total Debt

¥116.33B

Ono Pharmaceutical Performance Analysis

Ono Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 3,301,177,9722.7%
20242024-03-31JPY 3,480,784,4685.4%
20252025-03-31JPY 3,193,636,134-8.2%
20262026-03-31JPY 3,422,774,3307.2%
Ono Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-303.4%
Q32025-12-318.0%
Q42026-03-31-15.1%
Q12026-06-30-2.7%
Ono Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.5718.0%
20242024-03-31JPY 0.628.3%
20252025-03-31JPY 0.23-62.2%
20262026-03-31JPY 0.3341.1%
Ono Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3027.7%
Q32025-12-3130.3%
Q42026-03-31-97.2%
Q12026-06-302979.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥117.69B

-7.7%

Gross Profit

¥88.63B

-2.1%

Gross Margin

75.31%

N/A

Market Cap

$7.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.73M

N/A

Employees

4,206

N/A

Net Income

¥24.47B

+38.5%

EBITDA

¥40.69B

+30.3%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥219.74B

+57.9%

Total Debt

¥116.33B

-15.8%

Accounts Receivable

¥130.13B

-9.3%

Inventory

¥55.39B

-21.7%

Long Term Debt

¥74.30B

-29.4%

Short Term Debt

¥42.03B

+27.9%

Return on Assets

7.04%

N/A

Return on Invested Capital

11.70%

N/A

Free Cash Flow

-¥948.33M

-184.4%

Operating Cash Flow

¥1.07B

-68.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYKOFKyowa Kirin Co., Ltd.
$15.80+9.53%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
HKMPFHikma Pharmaceuticals PLC
$22.19+0.00%
HKMPYHikma Pharmaceuticals PLC
$43.18-0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About OPHLY

What is the current price of Ono Pharmaceutical?

Ono Pharmaceutical is trading at $5.30 per share.

What is the 52-week range for Ono Pharmaceutical?

Over the past 52 weeks, Ono Pharmaceutical has traded between $3.71 and $5.75.

How much debt does Ono Pharmaceutical have?

As of the most recent reporting period, Ono Pharmaceutical reported total debt of ¥720.50M.

How much cash does Ono Pharmaceutical have on hand?

Ono Pharmaceutical reported ¥1.35B in cash and cash equivalents in its most recent financial results.

What is Ono Pharmaceutical’s dividend yield?

Ono Pharmaceutical currently has a dividend yield of 3.26%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services